首页> 外文期刊>Open Chemistry >Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19
【24h】

Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19

机译:通过Covid-19受体的一些抗病毒药物的分子对接的计算研究是Covid-19药物的方法

获取原文
获取外文期刊封面目录资料

摘要

The COVID-19 outbreak is a matter of concern worldwide due to unavailability of promising treatment comprising medication or vaccination till date.The discovery of antiviral drug is of immense importance in the existing spread of novel coronavirus.The goal of the present study was to evolve an opposite antiviral drug against the novel COVID-19 virus.A directly succeeding perspective would be to use the prevailing influential drugs from several antimicrobial and chemotherapeutic agents.The encouraging approach is to identify promising drug molecules and compounds through virtual screening via molecular docking of FDA-approved drugs and some previously synthesized pyridone and?coumarin?derivatives for probable therapeutic outcome.In this conceptual milieu, an effort has been made to propose a computational?in silico?relationship among FDA-approved drugs and coronavirus-associated receptors and proteins.The study results were evaluated on the basis of a dock score by using molecular operating environment.Out of 15 compounds screened, the compounds with the best docking scores toward their targets was?3d.Therefore, compound?3d?deserves further investigations and clinical trials as a possible therapeutic inhibitor of the COVID-19 caused by the novel SARS-CoV-2.
机译:Covid-19爆发是全球令人担忧的问题,因为在迄今为止的有前途的治疗的不可用处理,抗病毒药物的发现在新的冠状病毒的现有传播中具有巨大的重要性。本研究的目标是进化针对新型Covid-19病毒的对抗抗病毒药物。直接成功的观点将是使用来自几种抗菌药和化学治疗剂的普遍的有影响力的药物。令人鼓舞的方法是通过通过分子对接的FDA来确定有前途的药物分子和化合物。 - 批准的药物和一些先前合成的吡啶酮和?香豆素?衍生物的可能治疗结果。在这种概念的环境中,已经努力提出计算?在硅中的计算?FDA批准的药物和冠状病毒相关的受体和蛋白质之间的关系。通过使用分子歌剧,基于码头评分评估研究结果筛选的环境。筛选的15种化合物,具有最佳对接得分的化合物是朝向其目标的基础是?3D。因此,化合物?3D?作为由新的SARS引起的Covid-19可能的治疗性抑制剂进一步调查和临床试验-cov-2。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号